Triapine(Triapine) - 药物靶点：RNRs_在研适应症：腺鳞癌，宫颈鳞状细胞癌，鳞状细胞癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Triapine、3-AP、NSC#663249

+ [5]

靶点

RNRs

作用方式

抑制剂

作用机制

RNR抑制剂(核糖核苷酸还原酶复合体抑制剂)

治疗领域

肿瘤泌尿生殖系统疾病其他疾病+ [3]

在研适应症

腺鳞癌宫颈鳞状细胞癌鳞状细胞癌+ [12]

非在研适应症

腺泡细胞癌急性早幼粒细胞白血病食管腺癌+ [57]

原研机构

Nanotherapeutics, Inc.

在研机构

National Cancer Institute

Nanotherapeutics, Inc.

Nanopharmaceutics, Inc.

非在研机构

Vion Pharmaceuticals, Inc.

权益机构

Resilience Government Services, Inc.

Trethera Corp.

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C7H9N5S

InChIKeyXMYKNCNAZKMVQN-UHFFFAOYSA-N

CAS号143621-35-6

关联

34

项与 Triapine 相关的临床试验

NCT06860594

/ Recruiting临床1期IIT

A Phase I Trial Combining Triapine With Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Giving triapine in combination with radiation therapy may be safe, tolerable, and/or effective in treating patients with recurrent glioblastoma or astrocytoma.

开始日期2026-03-01

申办/合作机构

National Cancer Institute

NCT06410248

/ Active, not recruiting临床1期IIT

A Phase 1 Adaptive Dose Escalation With Dose Expansion Study of Triapine in Combination With Temozolomide (TMZ) for Patients With Recurrent Glioblastoma

This phase I trial tests the safety, side effects, and best dose of triapine in combination with temozolomide in treating patients with glioblastoma that has come back after a period of improvement (recurrent). Triapine inhibits an enzyme responsible for producing molecules required for the production of deoxyribonucleic acid (DNA), which may inhibit tumor cell growth. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Giving triapine in combination with temozolomide may be safe, tolerable, and/or effective in treating patients with recurrent glioblastoma.

开始日期2024-07-23

申办/合作机构

Northwestern University

[+2]

NCT05724108

/ Recruiting临床2期IIT

A Phase II Randomized Control Trial of Triapine Plus Lutetium Lu 177 Dotatate Versus Lutetium Lu 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors

This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients with neuroendocrine tumors that have spread from where they first started (primary site) to other places in the body (metastatic). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for deoxyribonucleic acid synthesis and cell growth. Lutetium Lu 177 dotatate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177 dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving triapine in combination with lutetium Lu 177 dotatate may be more effective at shrinking tumors or slowing tumor growth in patients with metastatic neuroendocrine tumors than the standard therapy of lutetium Lu 177 dotatate alone.

开始日期2023-08-30

申办/合作机构

National Cancer Institute

100 项与 Triapine 相关的临床结果

登录后查看更多信息

100 项与 Triapine 相关的转化医学

登录后查看更多信息

100 项与 Triapine 相关的专利（医药）

登录后查看更多信息

413

项与 Triapine 相关的文献（医药）

2025-12-01·CANCER CHEMOTHERAPY AND PHARMACOLOGY

Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892)

Article

作者: Randall, Leslie M ; Vargo, John ; Kohn, Elise C ; Orr, Brian ; Courtney-Brooks, Madeleine ; Ivy, S Percy ; Mahdi, Haider ; Behr, Sarah ; Lin, Yan ; Fabian, Denise ; Beriwal, Sushil ; Gallion, Holly ; Richardson, Debra L ; Chu, Edward ; Beumer, Jan H ; Kunos, Charles ; Huang, Marilyn ; Taylor, Sarah E ; Ueland, Frederick ; Olawaiye, Alexander B ; Girda, Eugenia ; Sullivan, Stephanie A ; Chauhan, Aman ; Cooper, Kristine L ; Christner, Susan M

BACKGROUND:

The addition of IV triapine to chemoradiation appeared active in phase I and II studies but drug delivery is cumbersome. We examined PO triapine with cisplatin chemoradiation.

METHODS:

We implemented a 3 + 3 design for PO triapine dose escalation with expansion, starting at 100 mg, five days a week for five weeks while receiving radiation with weekly IV cisplatin for locally advanced cervical or vaginal cancer. Maximum tolerated dose (MTD), dose limiting toxicity (DLT), adverse events, pharmacokinetics (PK), pharmacodynamics (PD), and metabolic complete response (mCR) were assessed.

RESULTS:

19/21 patients were DLT evaluable. DLTs included grade 4 neutropenia (n = 2), leukopenia (n = 2), lymphopenia (n = 2), and hypokalemia (n = 1). Grade 3 toxicities at least possibly related were as expected for cisplatin chemoradiation: lymphopenia (n = 12), anemia (n = 10), neutropenia (n = 4), leukopenia (n = 8), decreased platelets (n = 2), hypertension (n = 1), and hyponatremia (n = 1). MTD and RP2D were established at 100 mg. 8/13 evaluable patients had a mCR. Triapine had a bioavailability of 59%. Methemoglobin levels correlated with triapine exposure. Smoking almost doubled CYP1A2 mediated triapine clearance.

CONCLUSIONS:

Oral triapine is safe when given with cisplatin chemoradiation, convenient, bioavailable. Exposure is negatively impacted by smoking, and methemoglobin is a biomarker of exposure.

CLINICAL TRIAL REGISTRATION:

NCT02595879.

2025-08-01·JOURNAL OF MOLECULAR HISTOLOGY

Does Moringa oleifera leaf extract protect the brain against 3-acetylpyridine-induced cerebellar ataxia in rat?

Review

作者: Sedeak, Ahmed Yahia ; Hassan, Doaa Mohamad ; Sabra, Nourhan Tharwat ; Farghaly, Maha Eid

There is no treatment for some neurological conditions, like cerebellar ataxia (CA). Moringa Oleifera (MO) has been revealed to have neuroprotective properties, but little is known about how it could protect against CA. In this study, we studied the neuroprotective effects of MO in an animal model of CA induced by 3-acetylpyridine (3-AP), which showed deficits in balance and motor coordination. Although cerebellar neuroinflammatory responses are evident in CA, it is yet unclear how neuroinflammation might influence CA. Here, we investigate whether MO, which has anti-inflammatory, antioxidant, and neuroprotective qualities, can help with cerebellar neurodegeneration and locomotor activity deficits. We divided 24 adult male rats into four equal groups. The control group received saline orally, the MO group received MO extract orally, the 3-AP group was injected with 3-AP, and the 3-AP + MO combined group received both 3-AP and MO for four weeks. The animals underwent a motor coordination test on the experiment's first and last days. At the end of the experiment, the animals were euthanized, the cerebellums were dissected, and they were then subjected to standard biochemical, histological, and immunohistochemical studies. The combined group showed remarkable improvement in the CA. The cerebellar neurodegeneration and declination of locomotor activity had improved. Our findings imply that MO may protect against the CA degenerative condition and improve cerebellar function.

2025-06-01·JOURNAL OF NEUROSCIENCE RESEARCH

Abscisic Acid Enhances Motor and Cognitive Function in the 3‐Acetylpyridine Mouse Model of Cerebellar Ataxia

Article

作者: Ranjbar, Hoda ; Kohlmeier, Kristi A. ; Soti, Monavareh ; Shabani, Mohammad ; Sabzalizadeh, Mansoureh ; Ilaghi, Mehran

ABSTRACT:

Cerebellar ataxia is a debilitating neurodegenerative disorder characterized by impaired motor coordination and balance with limited treatment options. Abscisic acid (ABA), a phytohormone detected in mammalian brains, has shown neuroprotective properties. This study investigated the effects of ABA on motor, cognitive, and affective deficits in a mouse model of cerebellar ataxia in which male Swiss mice received a single intraperitoneal injection of 3‐acetylpyridine (3‐AP; 60 mg/kg), which leads to the loss of climbing fiber input to Purkinje neurons leading to cerebellar degeneration. In ABA‐treated groups, ABA (10 or 15 μg/mouse) was intracerebroventricularly applied for four consecutive days. Behavioral testing consisted of open field, footprint analysis, wire grip, rotarod, tail suspension, elevated plus maze, Morris water maze, and the passive avoidance assay. Cerebellar brain‐derived neurotrophic factor (BDNF) levels were measured using ELISA. As expected, 3‐AP‐treated mice exhibited significant motor impairments, increased anxiety‐like and depressive‐like behaviors, and cognitive deficits. ABA treatment, particularly at the 15 μg/mouse dose, significantly improved motor coordination, locomotor activity, memory, and spatial and passive avoidance learning as well as reduced anxiety‐like and depressive‐like behaviors. Behavioral changes were associated with normalization of the 3‐AP‐induced increases in cerebellar BDNF levels. This study demonstrates that ABA can ameliorate motor, cognitive, and affective deficits in a mouse model of cerebellar ataxia, which could involve BDNF and be due to neuroprotective effects in the cerebellum. By extension, our data suggest that ABA may have therapeutic potential in the management of cerebellar ataxia and other cerebellar disorders.

5

项与 Triapine 相关的新闻（医药）

2025-07-18

·EINPresswire

Nanopharmaceutics Announces End of Patient Recruitment for NCI Phase II Study with Triapine for Neuroendocrine Tumors

Nanopharmaceutics Inc. Announces End of Patient Recruitment of NCI Phase II Clinical Study with Lutetium Lu 177 Dotatate +/- Triapine for Neuroendocrine Tumors TRON Group Inc (OTCMKTS:TGRP) ALACHUA, FL, UNITED STATES, July 18, 2025 / EINPresswire.com / -- ALACHUA, Fla., July 18, 2025 -- Nanopharmaceutics, Inc., a clinical-stage pharmaceutical development company, today announced completion of patient enrollment in the 94 patient Phase 2 clinical study “A Phase II Randomized Control Trial of Triapine Plus Lutetium Lu 177 Dotatate Versus Lutetium Lu 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors”. The study (NCI protocol 10558, ClinicalTrials.gov Identifier: NCT05724108) is sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, conducted by NCI funded Experimental Therapeutics Clinical Trials Network (ETCTN) with the Ohio State University Comprehensive Cancer Center as the lead institution. The randomized phase 2 trial is evaluating (PRIMARY OBJECTIVE) the overall response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 of combination Triapine ® + lutetium Lu 177 dotatate (treatment arm 1) versus standard of care lutetium Lu 177 dotatate alone (treatment arm 2) and (SECONDARY OBJECTIVE) to evaluate progression-free survival (PFS) between the two treatment arms (combination arm 1 versus standard of care arm 2). This phase II trial compares the effect of adding Triapine ® to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients with neuroendocrine tumors that have spread from where they first started (primary site) to other places in the body (metastatic). Triapine ® may stop the growth of tumor cells by blocking some of the enzymes needed for deoxyribonucleic acid synthesis and cell growth. Lutetium Lu 177 dotatate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177 dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. This study tests whether adding Triapine ® improves shrinking tumors or slowing tumor growth in patients with metastatic neuroendocrine tumors than the standard therapy of lutetium Lu 177 dotatate alone. 94 patients were enrolled in the study, which was performed under a Cooperative Research and Development Agreement (CRADA) between NCI and Nanopharmaceutics. The phase II trial passed the pre-planned interim safety review and interim futility assessment and is awaiting primary endpoint maturity. About Triapine ® Triapine ® is s synthetic heterocyclic carboxaldehyde thiosemicarbazone with potential antineoplastic activity being studied in the treatment of cancer. It is a type of ribonucleotide reductase inhibitor. Also called 3-aminopyridine-2-carboxaldehyde thiosemicarbazone and 3-AP, Triapine ® inhibits the enzyme ribonucleotide reductase, resulting in the inhibition of the conversion of ribonucleoside diphosphates to deoxyribonucleotides necessary for DNA synthesis. About Nanopharmaceutics, Inc. Nanopharmaceutics, Inc. is a clinical-stage specialty pharmaceutical company developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. Nanopharmaceutics is focused on formulation development aimed at improving drug absorption and stability. Nanopharmaceutics is a subsidiary of TRON Group Inc. (OTC:TGRP). James D. Talton, Ph.D. Nanopharmaceutics, Inc. +1 386-401-6304 email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

临床2期临床结果

2024-05-14

·PRNewswire

Nanopharmaceutics and Northwestern University Announce Initiation of Phase I Adaptive Dose Escalation Clinical Study with Dose Expansion of Oral Triapine® in Combination with Temozolomide (TMZ) for Patients with Recurrent Glioblastoma

ALACHUA, Fla. and CHICAGO, May 14, 2024 /PRNewswire/ -- Nanopharmaceutics, Inc. (OTC:TGRP), a clinical-stage pharmaceutical development company, announced the initiation of a Phase I clinical study with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University "A Phase 1 Adaptive Dose Escalation With Dose Expansion Study of Triapine in Combination With Temozolomide (TMZ) for Patients With Recurrent Glioblastoma" (ClinicalTrials.gov Identifier: NCT06410248). The primary objective of this phase 1 study will be to determine the recommended phase 2 dose (RP2D) for Triapine® in combination with temozolomide (TMZ). Secondary objectives include evaluation of the safety profile of Triapine® in combination with temozolomide (TMZ), progression-free survival (PFS), overall survival (OS), overall response rate (ORR) per RANO criteria, and quality of life per FACT-Br. The study will recruit 40-45 patients with an established diagnosis of recurrent glioblastoma, and there will be an exploratory arm to investigate drug delivery into brain tumor tissue and target engagement in a cohort who are surgical candidates for re-resection of recurrent glioblastoma. Funding for the study is provided by BrainUp. Oral Triapine® has been shown to be safe, tolerable, and convenient in multiple clinical studies. Ribonucleotide Reductase (RNR) Regulatory Subunit 2 (RRM2) targeting with Triapine® may overcome chemoresistance and improve the clinical efficacy of TMZ therapy. Preliminary research from Dr. Atique Ahmed's lab at Northwestern University has uncovered a critical factor that helps glioblastoma, an aggressive brain cancer, resist chemotherapy treatment. About the Robert H. Lurie Comprehensive Cancer Center of Northwestern University The Robert H. Lurie Comprehensive Cancer Center of Northwestern University is a National Cancer Institute-designated Comprehensive Cancer Center located on Northwestern Memorial Hospital's downtown medical campus in the Streeterville neighborhood of Chicago, Illinois, United States. About BrainUp BrainUp is a nonprofit founded by Dan & Meg Kresach of Frankfort, Illinois. They founded BrainUp after their only child Olivia, was diagnosed 10 years ago with a Glioblastoma at the age of 22 years old. She died on April 19, 2014. The Kresachs formed BrainUp to fund brain cancer research. They have an annual run/walk to raise money for brain cancer research. They have funded over 1.2 million dollars supporting brain cancer research and trials at Chicago healthcare institutions. BrainUp is the financial supporter of Karan Dixit, M.D. (PI) and Atique Ahmed, Ph.D of Northwestern University Chicago, Illinois. To learn more about BrainUp, visit brainup.ngo About Nanopharmaceutics, Inc. Nanopharmaceutics, Inc. is a clinical-stage specialty pharmaceutical company developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. Leveraging its expertise in nanoparticle and fine-particle formulations, which can specifically be used to improve hard-to-deliver BCS category II and IV drugs, Nanopharmaceutics is focused on formulation development aimed at improving drug absorption and stability. Contact: Nanopharmaceutics, Inc. (OTC: TGRP) James D. Talton, Ph.D. President and Chief Executive Officer 386-401-6304 SOURCE Nanopharmaceutics, Inc.

临床1期寡核苷酸

2022-11-02

·PRNewswire

Nanopharmaceutics, Inc. Announces the End of Patient Recruitment for the National Cancer Institute (NCI) Sponsored Phase 3 Clinical Study in Advanced-Stage Cervical and Vaginal Cancers with Cisplatin During Radiation Therapy with and without Triapine®

ALACHUA, Fla., Nov. 2, 2022 /PRNewswire/ -- Nanopharmaceutics, Inc., a clinical-stage pharmaceutical development company, today announced completion of patient enrollment in the 450 patient Phase 3 clinical study sponsored by the NCI, part of the National Institutes of Health, and led by NCI funded network group, NRG Oncology, with participation of the NCI National Clinical Trials Network (NCTN), "A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal," (NRG-GY006, ClinicalTrials.gov Identifier: NCT02466971). The randomized phase 3 trial is evaluating radiation therapy and cisplatin with Nanopharmaceutics' proprietary formulation of Triapine® compared to the standard radiation therapy and cisplatin, alone, in treating patients with newly diagnosed stage IB2, II, or IIIB-IVA cervical cancer or stage II-IVA vaginal cancer. Radiation therapy uses high energy protons to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, stopping them from dividing, or by stopping them from spreading. Triapine® may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether radiation therapy and cisplatin are more effective with Triapine® Injection in treating cervical or vaginal cancer. 450 patients were enrolled in the study, which was performed under a Cooperative Research and Development Agreement (CRADA) between NCI and Nanopharmaceutics. About Triapine® Triapine® is a synthetic heterocyclic carboxaldehyde thiosemicarbazone with potential antineoplastic activity being studied in the treatment of cancer. It is a type of ribonucleotide reductase inhibitor. Also called 3-aminopyridine-2-carboxaldehyde thiosemicarbazone and 3-AP, Triapine® inhibits the enzyme ribonucleotide reductase, resulting in the inhibition of the conversion of ribonucleoside diphosphates to deoxyribonucleotides necessary for DNA synthesis. About Nanopharmaceutics, Inc. Nanopharmaceutics, Inc. is a clinical-stage specialty pharmaceutical company developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. Leveraging its expertise in nanoparticle and fine-particle formulations, which can specifically be used to improve hard-to-deliver Biopharmaceutics Classification System (BCS) category II and IV drugs, Nanopharmaceutics is focused on formulation development aimed at improving drug absorption and stability. Contact: Nanopharmaceutics, Inc. James D. Talton, Ph.D. President and Chief Executive Officer 352-401-6304 [email protected] SOURCE Nanopharmaceutics, Inc.

放射疗法

100 项与 Triapine 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB11940

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
腺鳞癌	临床3期	美国	National Cancer Institute	2016-05-10
腺鳞癌	临床3期	加拿大	National Cancer Institute	2016-05-10
宫颈鳞状细胞癌	临床3期	美国	National Cancer Institute	2016-05-10
宫颈鳞状细胞癌	临床3期	加拿大	National Cancer Institute	2016-05-10
鳞状细胞癌	临床3期	美国	National Cancer Institute	2016-05-10
鳞状细胞癌	临床3期	加拿大	National Cancer Institute	2016-05-10
子宫颈腺癌	临床3期	美国	National Cancer Institute	2016-05-10
子宫颈腺癌	临床3期	加拿大	National Cancer Institute	2016-05-10
阴道腺癌	临床3期	美国	National Cancer Institute	2016-05-10
阴道腺癌	临床3期	加拿大	National Cancer Institute	2016-05-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02595879 (ETCTN 9892, Pubmed \| Cancer Chemother Pharmacol)	临床1/2期	阴道腺癌 \| 局部晚期宫颈癌 methemoglobin levels \| smoking \| CYP1A2	21	Oral Triapine 100 mg	繭膚鏇製鹹選繭築壓夢(觸餘襯繭憲簾齋鏇範窪) = almost doubled CYP1A2 mediated triapine clearance 鑰願衊窪簾齋選衊積積 (壓鑰選鬱醖選構鏇夢選 ) 更多	积极	2025-12-01
NCT02595879 (ETCTN 9892, CTgov)	临床1期	腺鳞癌 \| 阴道腺癌 \| 局部晚期宫颈癌 ... 更多	21	triapine (All Participants)	鬱製鏇製膚壓鹹範構鹹 = 鏇壓膚醖簾襯觸積簾觸獵艱鹹製襯繭觸餘選繭 (憲夢製構衊鹽築顧廠襯, 憲窪積願壓鹽淵蓋選蓋 ~ 窪鬱齋製醖夢鬱憲醖簾)	-	2024-10-16
				Triapine (Triapine (100mg) + Chemoradiation))	淵製衊範構膚獵餘鹽壓 = 艱顧糧網構醖糧衊鹹範製製艱艱窪積蓋憲鏇夢 (遞鹽壓顧膚遞餘膚製積, 鹽構構積顧壓繭鑰壓繭 ~ 鑰鏇願鬱衊鹹衊繭願鏇) 更多
NCT02466971 (NRG-GY006, CTgov)	临床3期	腺鳞癌 \| 阴道腺癌 \| 宫颈鳞状细胞癌 ... 更多	450	Intensity-Modulated Radiation Therapy+cisplatin (Arm I (Cisplatin, IMRT or RT, Brachytherapy))	範積觸繭願醖廠選壓簾 = 餘鏇範範製壓憲網衊窪獵衊糧蓋獵製淵鹽艱襯 (憲築鏇醖壓構願蓋廠鹽, 繭餘鑰淵積衊廠艱憲膚 ~ 鹽製範膚齋壓蓋窪鹽網) 更多	-	2024-01-05
				Intensity-Modulated Radiation Therapy+Triapine+cisplatin (Arm II (Cisplatin, IMRT or RT, Brachytherapy, Triapine))	範積觸繭願醖廠選壓簾 = 顧襯膚願鹹壓鹹製窪範獵衊糧蓋獵製淵鹽艱襯 (憲築鏇醖壓構願蓋廠鹽, 糧積窪鹹膚積鏇壓構觸 ~ 構壓蓋網鑰膚構鑰醖鹽) 更多
NCT02466971 (NRG-GY006, ASCO2023)	临床3期	阴道肿瘤 \| 局部晚期宫颈癌	448	Cisplatin + RT	淵網齋製願獵繭願繭鏇(餘築遞願齋鬱鏇構餘糧): HR = 1.018 (95% CI, 0.634 ~ 1.635) 更多	不佳	2023-05-31
				Cisplatin + RT + Triapine
NCT04234568 (AACR2023) 人工标引	临床1期	胃肠胰神经内分泌肿瘤 SSTR Expression	31	triapine+Lutetium Dotatate LU-177	醖膚願壓糧膚餘遞積夢(餘衊製簾膚製廠選衊鏇) = One DLT in dose level 1, seven DLTs in dose level 2, and one grade 5 DLT in dose level 3 were observed. 餘選積鏇餘夢醖鏇遞鏇 (鏇鹹壓獵憲壓衊鏇簾範 ) 更多	积极	2023-04-14
NCT04234568 (ASCO_GI2023) 人工标引	临床1期	SSTR阳性胃肠胰神经内分泌肿瘤 SSTR1 Expression	31	triapine+lutetium Lu-177 dotatate	繭廠積壓構鹹鑰蓋夢鬱(憲鏇廠齋顧築餘構艱窪) = 廠憲鑰製艱鏇積構獵築衊築獵夢鹹淵艱艱艱獵 (鑰糧鹹衊鹹鹽窪觸獵襯 ) 更多	积极	2023-01-24
NCT04234568 (ASCO2020)	临床1期	神经内分泌肿瘤一线	29	Triapine and Lutetium Lu 177 Dotatate	觸醖壓壓製獵淵顧遞壓(繭膚獵膚選膚網構壓憲) = 鏇夢願壓簾廠憲壓壓選鏇蓋衊範構願獵鹹齋鑰 (製願願蓋遞鹹蓋繭繭積 )	-	2020-05-25
NCT02466971 (Pubmed \| Front Oncol) 人工标引	临床2期	阴道肿瘤 \| 子宫颈疾病	26	cisplatin+Radiotherapy+triapine	獵遞願鬱繭糧網廠鹽構(鑰構製遞觸鑰簾鹽鹹壓) = 膚獵鏇鏇膚觸獵夢壓夢範網窪選壓齋窪鹽淵觸 (選窪窪膚鑰襯鑰膚觸選 ) 更多	积极	2019-10-15
				cisplatin+Radiotherapy	獵遞願鬱繭糧網廠鹽構(鑰構製遞觸鑰簾鹽鹹壓) = 製鏇蓋膚窪網醖鹹鹽糧範網窪選壓齋窪鹽淵觸 (選窪窪膚鑰襯鑰膚觸選 ) 更多
NCT00016874 (Pubmed \| Front Oncol) 人工标引	临床1期	实体瘤	13	cisplatin+paclitaxel+triapine	廠膚鹹鑰鏇顧鬱蓋遞壓(齋積鏇願觸壓憲顧選鏇) = triapine (80 mg/m2), cisplatin (50 mg/m2), paclitaxel (80 mg/m2) 淵鬱築襯積鬱鏇鏇蓋糧 (齋衊憲窪鹹製範蓋鏇製 ) 更多	积极	2017-04-04
NCT00024323 (Pubmed \| Cancer Chemother Pharmacol)	临床1期	肿瘤	-	Triapine	膚蓋齋顧醖顧製鑰網製(願獵繭襯選願構艱積憲) = 鬱餘觸選獵鹽選顧齋鏇壓餘廠廠餘襯衊廠壓範 (鬱鑰艱觸憲憲醖願獵蓋 )	-	2017-01-01
				Cisplatin	膚蓋齋顧醖顧製鑰網製(願獵繭襯選願構艱積憲) = 鑰膚廠夢簾鹽淵蓋網窪壓餘廠廠餘襯衊廠壓範 (鬱鑰艱觸憲憲醖願獵蓋 )